Elsevier launches PharmaPendium AI, designed to support faster and more reliable access to regulatory insights for drug development
(NYSE:RELX) The solution transforms how insights are gathered from regulatory data, enabling users to quickly identify critical precedents, anticipate approval issues and avoid costly missteps LOND...
What is the expected adoption rate among pharmaceutical companies and how might this influence RELX's market share and valuation multiples?
What is the competitive landscape for AI-driven regulatory insight platforms, and how does Elsevier's offering compare to rivals like Clarivate and IBM?
How will the launch of PharmaPendium AI affect RELX's revenue growth and earnings forecasts?
11 days ago